

## AMENDMENTS

***Please amend the Claims as follows:***

Claims 1-37 (Cancelled)

38. (Currently Amended) A purified and isolated hyperimmune serum-reactive *S. pneumoniae* antigen that is immunologically reactive with sera from a human having an *S. pneumoniae* infection or an uninfected healthy human, the antigen comprising an isolated *S. pneumoniae* polypeptide or peptide fragment thereof that is:

a) a polypeptide Sp-2246 having an amino acid sequence identified by SEQ ID NO. 243;

b) an antigenic peptide fragment comprising an amino acid sequence defined by amino acids 1-285 of the amino acid sequence identified by SEQ ID NO: 243; or

c) an antigenic peptide fragment comprising an amino acid sequence defined by amino acids 15-37, 32-57, 101-151, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243.

wherein each of said polypeptides or antigenic peptide fragments comprises an epitope capable of eliciting an immunological reaction in a human.

39. (Cancelled)

40. (Currently Amended) An *S. pneumoniae* antigen according to claim 38, wherein the antigen is an isolated *S. pneumoniae* polypeptide that is Sp 2216 identified by SEQ ID NO: 243 (~~SEQ ID NO. 243~~).

41. (Currently Amended) An *S. pneumoniae* antigen according to claim 38, wherein the antigen is an isolated antigenic peptide fragment defined by amino acids 1-285 of ~~*S. pneumoniae*~~ polypeptide ~~Sp 2246 having an amino acid sequence identified by~~ SEQ ID NO. 243.

42. (Cancelled)

43. (Currently Amended) An *S. pneumoniae* antigen according to claim ~~38~~40, ~~wherein the antigen is a~~ that is an antigenic peptide fragment of the isolated *S. pneumoniae* polypeptide

~~comprising an amino acid sequence defined by amino acids 4-25, 52-67, 117-124, 131-146, 173-180, 182-191, 195-206, 215-221, 229-236, 245-252, 258-270, 286-291, 293-302, 314-320, 327-336, 341-353, 355-361, 383-389, 15-37, 32-57, 101-151, 115-135, 138-158, 152-172, 220-242 or 236-258 of SEQ ID NO. 243.~~

44. (Currently Amended) A pharmaceutical composition comprising at least one antigen according to any of claims 38, 40, 41, or 43, and optionally a pharmaceutically-acceptable carrier or excipient.

45. (Original) A pharmaceutical composition according to claim 44, further comprising an immunostimulatory substance.

46. (Original) A pharmaceutical composition according to claim 45, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two Lys-Leu-Lys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.

47. (Cancelled)

48. (Original) A pharmaceutical composition according to claim 44 that is a vaccine.

Claims 49 through 68. (Cancelled)